6.17
2.15%
+0.13
After Hours:
6.16
-0.010
-0.16%
Emergent Biosolutions Inc stock is currently priced at $6.17, with a 24-hour trading volume of 1.67M.
It has seen a +2.15% increased in the last 24 hours and a +21.46% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.17 pivot point. If it approaches the $5.87 support level, significant changes may occur.
Previous Close:
$6.04
Open:
$5.95
24h Volume:
1.67M
Market Cap:
$323.32M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.5108
EPS:
-12.08
Net Cash Flow:
$-257.90M
1W Performance:
-0.32%
1M Performance:
+21.46%
6M Performance:
+143.87%
1Y Performance:
-23.16%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
400 Professional Drive, Gaithersburg, MD
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
May-05-21 | Downgrade | Argus | Buy → Hold |
Apr-07-21 | Initiated | The Benchmark Company | Buy |
Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-14-20 | Resumed | JP Morgan | Neutral |
Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
Sep-12-19 | Initiated | Guggenheim | Buy |
Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
Jun-13-18 | Initiated | Argus | Buy |
Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jan-24-18 | Initiated | Goldman | Neutral |
Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
Jun-28-16 | Reiterated | Singular Research | Buy |
Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
Mar-28-16 | Initiated | Singular Research | Buy |
Feb-19-16 | Initiated | Wells Fargo | Outperform |
May-15-14 | Initiated | Summer Street Research | Buy |
May-31-11 | Reiterated | WBB Securities | Strong Buy |
Jan-10-11 | Reiterated | Wedbush | Outperform |
Nov-05-10 | Reiterated | Wedbush | Outperform |
Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
EBS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
The InvestChronicle
Emergent Biosolutions Inc (EBS) Forecast: Revisiting The Past To Gain Insights For The Future – Stocks Register - Stocks Register
Stocks Register
Emergent BioSolutions (NYSE:EBS) Stock Passes Above Two Hundred Day Moving Average of $2.88 - Defense World
Defense World
Was anything negative for Emergent Biosolutions Inc (EBS) stock last session? – US Post News - US Post News
US Post News
Ratios Uncovered: Breaking Down Emergent Biosolutions Inc (EBS)'s Trailing Twelve Months Metrics – DWinneX - The Dwinnex
The Dwinnex
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9% - Yahoo New Zealand News
Yahoo New Zealand News
Emergent Biosolutions Inc Stock (EBS) Financials Data
Emergent Biosolutions Inc (EBS) Revenue 2024
EBS reported a revenue (TTM) of $1.02 billion for the quarter ending December 31, 2023, a -5.11% decline year-over-year.
Emergent Biosolutions Inc (EBS) Net Income 2024
EBS net income (TTM) was -$757.20 million for the quarter ending December 31, 2023, a -253.50% decrease year-over-year.
Emergent Biosolutions Inc (EBS) Cash Flow 2024
EBS recorded a free cash flow (TTM) of -$257.90 million for the quarter ending December 31, 2023, a -72.05% decrease year-over-year.
Emergent Biosolutions Inc (EBS) Earnings per Share 2024
EBS earnings per share (TTM) was -$14.76 for the quarter ending December 31, 2023, a -213.38% decline year-over-year.
About Emergent Biosolutions Inc
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Cap:
|
Volume (24h):